JP2018502925A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018502925A5 JP2018502925A5 JP2017556797A JP2017556797A JP2018502925A5 JP 2018502925 A5 JP2018502925 A5 JP 2018502925A5 JP 2017556797 A JP2017556797 A JP 2017556797A JP 2017556797 A JP2017556797 A JP 2017556797A JP 2018502925 A5 JP2018502925 A5 JP 2018502925A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- optionally substituted
- halo
- independently
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 140
- 125000005843 halogen group Chemical group 0.000 claims description 70
- 229910052799 carbon Inorganic materials 0.000 claims description 36
- 150000001875 compounds Chemical class 0.000 claims description 36
- 125000003545 alkoxy group Chemical group 0.000 claims description 34
- 125000003118 aryl group Chemical group 0.000 claims description 32
- 125000001072 heteroaryl group Chemical group 0.000 claims description 32
- 125000005842 heteroatom Chemical group 0.000 claims description 26
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 22
- 125000000623 heterocyclic group Chemical group 0.000 claims description 22
- 229910052739 hydrogen Inorganic materials 0.000 claims description 22
- 229910052760 oxygen Inorganic materials 0.000 claims description 22
- 230000001588 bifunctional effect Effects 0.000 claims description 20
- 125000004429 atom Chemical group 0.000 claims description 16
- 125000004122 cyclic group Chemical group 0.000 claims description 16
- 125000001188 haloalkyl group Chemical group 0.000 claims description 16
- 125000002723 alicyclic group Chemical group 0.000 claims description 14
- 125000003342 alkenyl group Chemical group 0.000 claims description 14
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 12
- 229910052717 sulfur Inorganic materials 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 10
- 102000001307 androgen receptors Human genes 0.000 claims description 10
- 108010080146 androgen receptors Proteins 0.000 claims description 10
- -1 hydroxylprolyl moiety Chemical group 0.000 claims description 10
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 10
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 claims description 8
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 claims description 8
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 8
- 125000005647 linker group Chemical group 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 4
- PIGFYZPCRLYGLF-UHFFFAOYSA-N Aluminum nitride Chemical compound [Al]#N PIGFYZPCRLYGLF-UHFFFAOYSA-N 0.000 claims description 4
- 125000005099 aryl alkyl carbonyl group Chemical group 0.000 claims description 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 4
- 125000005129 aryl carbonyl group Chemical group 0.000 claims description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- VLJNHYLEOZPXFW-UHFFFAOYSA-N pyrrolidine-2-carboxamide Chemical compound NC(=O)C1CCCN1 VLJNHYLEOZPXFW-UHFFFAOYSA-N 0.000 claims description 4
- 125000005415 substituted alkoxy group Chemical group 0.000 claims description 4
- 125000003107 substituted aryl group Chemical group 0.000 claims description 4
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- XXTZLIAFLLLNOR-USAYTKQKSA-N (2S,4R)-1-[(2S)-2-amino-3,3-dimethylbutanoyl]-N-[(4-chlorophenyl)methyl]-4-hydroxypyrrolidine-2-carboxamide hydrochloride Chemical compound Cl.CC(C)(C)[C@H](N)C(=O)N1C[C@H](O)C[C@H]1C(=O)NCc1ccc(Cl)cc1 XXTZLIAFLLLNOR-USAYTKQKSA-N 0.000 claims description 2
- PAQNZLPEBCDUAS-GBEOHXTHSA-N (2S,4R)-1-[(2S)-2-amino-3,3-dimethylbutanoyl]-N-[(4-cyanophenyl)methyl]-4-hydroxypyrrolidine-2-carboxamide hydrochloride Chemical compound Cl.CC(C)(C)[C@H](N)C(=O)N1C[C@H](O)C[C@H]1C(=O)NCc1ccc(cc1)C#N PAQNZLPEBCDUAS-GBEOHXTHSA-N 0.000 claims description 2
- ZLOXMSNKPDWMEF-ZIFCJYIRSA-N (2s,4r)-1-[(2s)-2-amino-3,3-dimethylbutanoyl]-4-hydroxy-n-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide Chemical compound N1=CSC(C=2C=CC(CNC(=O)[C@H]3N(C[C@H](O)C3)C(=O)[C@@H](N)C(C)(C)C)=CC=2)=C1C ZLOXMSNKPDWMEF-ZIFCJYIRSA-N 0.000 claims description 2
- 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 claims description 2
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 2
- 208000027747 Kennedy disease Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 239000012867 bioactive agent Substances 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 2
- 230000000155 isotopic effect Effects 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 239000000651 prodrug Substances 0.000 claims description 2
- 229940002612 prodrug Drugs 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562105210P | 2015-01-20 | 2015-01-20 | |
| US62/105,210 | 2015-01-20 | ||
| PCT/US2016/014187 WO2016118666A1 (en) | 2015-01-20 | 2016-01-20 | Compounds and methods for the targeted degradation of the androgen receptor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020046636A Division JP2020111590A (ja) | 2015-01-20 | 2020-03-17 | ターゲティングされたアンドロゲン受容体分解のための化合物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018502925A JP2018502925A (ja) | 2018-02-01 |
| JP2018502925A5 true JP2018502925A5 (enExample) | 2018-09-27 |
| JP6817962B2 JP6817962B2 (ja) | 2021-01-20 |
Family
ID=56417710
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017556797A Active JP6817962B2 (ja) | 2015-01-20 | 2016-01-20 | ターゲティングされたアンドロゲン受容体分解のための化合物および方法 |
| JP2020046636A Pending JP2020111590A (ja) | 2015-01-20 | 2020-03-17 | ターゲティングされたアンドロゲン受容体分解のための化合物および方法 |
| JP2022206686A Pending JP2023040072A (ja) | 2015-01-20 | 2022-12-23 | ターゲティングされたアンドロゲン受容体分解のための化合物および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020046636A Pending JP2020111590A (ja) | 2015-01-20 | 2020-03-17 | ターゲティングされたアンドロゲン受容体分解のための化合物および方法 |
| JP2022206686A Pending JP2023040072A (ja) | 2015-01-20 | 2022-12-23 | ターゲティングされたアンドロゲン受容体分解のための化合物および方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11352351B2 (enExample) |
| EP (1) | EP3247708A4 (enExample) |
| JP (3) | JP6817962B2 (enExample) |
| KR (5) | KR20220029783A (enExample) |
| CN (1) | CN107428734A (enExample) |
| AU (4) | AU2016209349B2 (enExample) |
| BR (1) | BR112017015497A2 (enExample) |
| CA (1) | CA2974367A1 (enExample) |
| HK (2) | HK1245791A1 (enExample) |
| MX (2) | MX390189B (enExample) |
| WO (1) | WO2016118666A1 (enExample) |
Families Citing this family (160)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3608317A1 (en) | 2012-01-12 | 2020-02-12 | Yale University | Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase |
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| US10071164B2 (en) | 2014-08-11 | 2018-09-11 | Yale University | Estrogen-related receptor alpha based protac compounds and associated methods of use |
| HK1245791A1 (zh) | 2015-01-20 | 2018-08-31 | 阿尔维纳斯运营股份有限公司 | 用於雄激素受体的靶向降解的化合物和方法 |
| US12312316B2 (en) | 2015-01-20 | 2025-05-27 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| GB201504314D0 (en) * | 2015-03-13 | 2015-04-29 | Univ Dundee | Small molecules |
| HK1249058A1 (zh) * | 2015-03-18 | 2018-10-26 | Arvinas, Inc. | 用於增强靶向蛋白质降解的化合物和方法 |
| WO2016197114A1 (en) | 2015-06-05 | 2016-12-08 | Arvinas, Inc. | Tank-binding kinase-1 protacs and associated methods of use |
| CA2988430A1 (en) * | 2015-07-10 | 2017-01-19 | Arvinas, Inc. | Mdm2-based modulators of proteolysis and associated methods of use |
| EP3331905B1 (en) | 2015-08-06 | 2022-10-05 | Dana-Farber Cancer Institute, Inc. | Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses |
| WO2017030814A1 (en) | 2015-08-19 | 2017-02-23 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| US9963433B2 (en) * | 2016-01-29 | 2018-05-08 | Wayne State University | Anticancer drugs including the chemical structures of an androgen receptor ligand and a histone deacetylase inhibitor |
| EP3445357B1 (en) | 2016-04-22 | 2021-05-26 | Dana-Farber Cancer Institute, Inc. | Bifunctional molecules for degradation of egfr and methods of use |
| EP3455218A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| CN109562107A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
| EP4483875A3 (en) | 2016-05-10 | 2025-04-02 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| GB2554071A (en) * | 2016-09-14 | 2018-03-28 | Univ Dundee | Small molecules |
| WO2018053354A1 (en) * | 2016-09-15 | 2018-03-22 | Arvinas, Inc. | Indole derivatives as estrogen receptor degraders |
| US10584101B2 (en) | 2016-10-11 | 2020-03-10 | Arvinas, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| WO2018102067A2 (en) | 2016-11-01 | 2018-06-07 | Arvinas, Inc. | Tau-protein targeting protacs and associated methods of use |
| EP3535254A4 (en) * | 2016-11-01 | 2020-06-24 | Cornell University Cornell Center For Technology, Enterprise & Commercialization ("CCTEC") | COMPOUNDS FOR THE DEGRADATION OF MALT1 |
| JP6957620B2 (ja) | 2016-12-01 | 2021-11-02 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | エストロゲン受容体分解物質としてのテトラヒドロナフタレン誘導体およびテトラヒドロイソキノリン誘導体 |
| KR20250117470A (ko) | 2016-12-23 | 2025-08-04 | 아비나스 오퍼레이션스, 인코포레이티드 | 급속 진행성 섬유육종 폴리펩티드의 표적화 분해를 위한 화합물 및 방법 |
| EP3559006A4 (en) | 2016-12-23 | 2021-03-03 | Arvinas Operations, Inc. | COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF F TAL LIVER KINASE POLYPEPTIDES |
| US11173211B2 (en) | 2016-12-23 | 2021-11-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides |
| JP2020505327A (ja) | 2016-12-23 | 2020-02-20 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | Ｅｇｆｒタンパク質分解標的化キメラ分子およびその関連する使用方法 |
| US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
| JP7266526B6 (ja) | 2017-01-26 | 2024-02-15 | アルビナス・オペレーションズ・インコーポレイテッド | エストロゲン受容体タンパク質分解性の調節因子およびその関連方法 |
| CA3050309A1 (en) | 2017-01-31 | 2018-08-09 | Arvinas Operations, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| WO2018148440A1 (en) | 2017-02-08 | 2018-08-16 | Dana-Farber Cancer Institute, Inc. | Regulating chimeric antigen receptors |
| EP3615083A4 (en) | 2017-04-28 | 2021-05-19 | Zamboni Chem Solutions Inc. | RAF DEGRADATION CONJUGATES |
| WO2018204422A1 (en) | 2017-05-01 | 2018-11-08 | Spg Therapeutics, Inc. | Tripartite androgen receptor eliminators, methods and uses thereof |
| CN108976278B (zh) * | 2017-06-05 | 2021-04-06 | 海创药业股份有限公司 | 一种嵌合分子及其制备和应用 |
| CN118440096A (zh) | 2017-06-20 | 2024-08-06 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| SG10202110500TA (en) | 2017-06-22 | 2021-11-29 | Catalyst Biosciences Inc | Modified membrane type serine protease 1 (mtsp-1) polypeptides and methods of use |
| CA3069544A1 (en) * | 2017-07-28 | 2019-01-31 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| WO2019043208A1 (en) | 2017-09-04 | 2019-03-07 | F. Hoffmann-La Roche Ag | DIHYDROQUINOLINONES |
| CN118108706A (zh) | 2017-09-04 | 2024-05-31 | C4医药公司 | 戊二酰亚胺 |
| EP3679027A1 (en) | 2017-09-04 | 2020-07-15 | C4 Therapeutics, Inc. | Dihydrobenzimidazolones |
| US11834430B2 (en) | 2017-09-12 | 2023-12-05 | Agency For Science, Technology And Research | Compounds useful as inhibitors of isoprenylcysteine carboxyl methyltransferase |
| IL273432B (en) | 2017-09-22 | 2022-09-01 | Kymera Therapeutics Inc | Protein compounds and their uses |
| US11358948B2 (en) | 2017-09-22 | 2022-06-14 | Kymera Therapeutics, Inc. | CRBN ligands and uses thereof |
| WO2019099868A2 (en) | 2017-11-16 | 2019-05-23 | C4 Therapeutics, Inc. | Degraders and degrons for targeted protein degradation |
| EP3710443A1 (en) | 2017-11-17 | 2020-09-23 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides |
| CN107987055A (zh) * | 2017-12-19 | 2018-05-04 | 刘秀云 | 硫代咪唑二酮类雄激素受体拮抗剂及其用途 |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| WO2019140380A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| EP3737675A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
| US11220515B2 (en) | 2018-01-26 | 2022-01-11 | Yale University | Imide-based modulators of proteolysis and associated methods of use |
| CN111902141A (zh) | 2018-03-26 | 2020-11-06 | C4医药公司 | 用于ikaros降解的羟脑苷脂结合剂 |
| US12539292B2 (en) | 2018-04-01 | 2026-02-03 | Arvinas Operations, Inc. | BRM targeting compounds and associated methods of use |
| EP3774789B1 (en) * | 2018-04-01 | 2025-03-05 | Arvinas Operations, Inc. | Brm targeting compounds and associated methods of use |
| JP7720698B2 (ja) | 2018-04-04 | 2025-08-08 | アルビナス・オペレーションズ・インコーポレイテッド | タンパク質分解の調節因子および関連する使用方法 |
| EP3781156A4 (en) | 2018-04-16 | 2022-05-18 | C4 Therapeutics, Inc. | SPIROCYCLIC COMPOUNDS |
| KR20210018291A (ko) | 2018-05-14 | 2021-02-17 | 누베이션 바이오 인크. | 항암 핵 호르몬 수용체-표적화 화합물 |
| WO2019218904A1 (zh) * | 2018-05-18 | 2019-11-21 | 四川科伦博泰生物医药股份有限公司 | 非天然氨基酸类衍生物、其制备方法及用途 |
| EP3578561A1 (en) | 2018-06-04 | 2019-12-11 | F. Hoffmann-La Roche AG | Spiro compounds |
| CN110684046B (zh) * | 2018-07-06 | 2023-05-12 | 江苏恒瑞医药股份有限公司 | 一种新的咪唑啉类衍生物的制备方法 |
| EP3817822A4 (en) | 2018-07-06 | 2022-07-27 | Kymera Therapeutics, Inc. | PROTEIN DEGRADANTS AND USES THEREOF |
| WO2020010177A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Tricyclic crbn ligands and uses thereof |
| CN110746399B (zh) * | 2018-07-23 | 2022-04-22 | 上海美志医药科技有限公司 | 具有降解雄激素受体活性的化合物 |
| JP7515175B2 (ja) | 2018-07-31 | 2024-07-12 | ファイメクス株式会社 | 複素環化合物 |
| WO2020041331A1 (en) | 2018-08-20 | 2020-02-27 | Arvinas Operations, Inc. | Proteolysis targeting chimeric (protac) compound with e3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurodegenerative diseases |
| EP3846800A4 (en) | 2018-09-04 | 2022-08-24 | C4 Therapeutics, Inc. | Compounds for the degradation of brd9 or mth1 |
| CA3121202A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| CA3119773A1 (en) | 2018-11-30 | 2020-06-04 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| CN109762045A (zh) * | 2018-12-14 | 2019-05-17 | 中山大学附属第一医院 | 一种双靶点构建protac的方法及其用途 |
| KR20250144505A (ko) | 2018-12-19 | 2025-10-10 | 셀진 코포레이션 | 치환된 3-((3-아미노페닐)아미노)피페리딘-2,6-디온 화합물, 이의 조성물, 및 이를 사용한 치료 방법 |
| WO2020132016A1 (en) | 2018-12-19 | 2020-06-25 | Celgene Corporation | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith |
| CN113453679B (zh) | 2018-12-20 | 2025-07-08 | C4医药公司 | 靶向蛋白降解 |
| US20220081435A1 (en) * | 2019-01-03 | 2022-03-17 | The Regents Of The University Of Michigan | Androgen receptor protein degraders |
| US11547759B2 (en) | 2019-01-30 | 2023-01-10 | Montelino Therapeutics, Inc. | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor |
| CN113677668B (zh) * | 2019-01-30 | 2024-09-27 | 蒙特利诺治疗公司 | 用于雄激素受体靶向泛素化的双官能化合物和方法 |
| CN113660937A (zh) * | 2019-02-08 | 2021-11-16 | 佛罗里达大学研究基金公司 | 治疗剂和治疗方法 |
| WO2020181232A1 (en) | 2019-03-06 | 2020-09-10 | C4 Therapeutics, Inc. | Heterocyclic compounds for medical treatment |
| WO2020198055A1 (en) * | 2019-03-22 | 2020-10-01 | Yale University | Allosteric bcr-abl proteolysis targeting chimeric compounds |
| EP3950678A4 (en) * | 2019-04-02 | 2023-04-26 | Hinova Pharmaceuticals Inc. | AROMATIC AMINE COMPOUND AND ITS USE IN THE PREPARATION OF DUAL AR AND BRD4 INHIBITORS AND REGULATORS |
| CN120574283A (zh) | 2019-04-05 | 2025-09-02 | 凯麦拉医疗公司 | Stat降解剂和其用途 |
| CN113677664B (zh) | 2019-04-12 | 2025-04-04 | C4医药公司 | Ikaros和aiolos的三环降解物 |
| WO2020214555A1 (en) | 2019-04-16 | 2020-10-22 | Northwestern University | Bifunctional compounds comprising apcin-a and their use in the treatment of cancer |
| CN119504751B (zh) * | 2019-04-18 | 2025-11-14 | 海创药业股份有限公司 | 一类靶向降解雄激素受体的双功能嵌合体杂环化合物及其用途 |
| MA55909A (fr) | 2019-05-05 | 2022-03-16 | Qilu Regor Therapeutics Inc | Inhibiteurs de cdk |
| GB201906705D0 (en) | 2019-05-13 | 2019-06-26 | Phoremost Ltd | Methods |
| CN113811333B (zh) | 2019-05-14 | 2024-03-12 | 诺维逊生物股份有限公司 | 靶向抗癌核激素受体的化合物 |
| WO2020233512A1 (zh) * | 2019-05-17 | 2020-11-26 | 成都海创药业有限公司 | 一种芳香胺类靶向ar和bet的蛋白降解嵌合体化合物及用途 |
| WO2020251972A1 (en) | 2019-06-10 | 2020-12-17 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
| AU2020302118A1 (en) | 2019-06-28 | 2022-02-24 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| WO2021011913A1 (en) | 2019-07-17 | 2021-01-21 | Arvinas Operations, Inc. | Tau-protein targeting compounds and associated methods of use |
| CN112390852B (zh) * | 2019-08-14 | 2022-10-18 | 上海济煜医药科技有限公司 | 作为蛋白降解剂的化合物及其制备方法和应用 |
| MX2022002415A (es) | 2019-08-26 | 2022-03-22 | Arvinas Operations Inc | Metodos de tratamiento del cancer de mama con derivados de tetrahidronaftaleno como degradadores del receptor de estrogenos. |
| CN118085015A (zh) * | 2019-09-06 | 2024-05-28 | 江西济民可信集团有限公司 | 作为蛋白降解剂的并环类化合物及其制备方法和用途 |
| CN112457367B (zh) * | 2019-09-06 | 2022-08-23 | 上海济煜医药科技有限公司 | 作为蛋白降解剂的连环类化合物及其制备方法和应用 |
| CN112574278B (zh) * | 2019-09-29 | 2024-08-23 | 江西济民可信集团有限公司 | 作为蛋白降解剂杂环类化合物及其制备方法和医药应用 |
| CN115397821B (zh) | 2019-10-17 | 2024-09-03 | 阿尔维纳斯运营股份有限公司 | 含有与bcl6靶向部分连接的e3泛素连接酶结合部分的双官能分子 |
| US11952349B2 (en) | 2019-11-13 | 2024-04-09 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| CN110845348A (zh) * | 2019-12-10 | 2020-02-28 | 苏州国匡医药科技有限公司 | 一种arv-110中间体的制备方法 |
| JP2023509366A (ja) | 2019-12-17 | 2023-03-08 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋ分解剤およびそれらの使用 |
| EP4076524A4 (en) | 2019-12-17 | 2023-11-29 | Kymera Therapeutics, Inc. | IRAQ DEGRADERS AND USES THEREOF |
| PE20221582A1 (es) | 2019-12-19 | 2022-10-06 | Arvinas Operations Inc | Compuestos y metodos para la degradacion dirigida de receptor de androgenos |
| PE20230114A1 (es) * | 2019-12-23 | 2023-01-27 | Shanghai Jemincare Pharmaceuticals Co Ltd | Metodo y aplicacion de preparacion de compuesto como agente de degradacion de proteinas |
| CN115297931A (zh) | 2019-12-23 | 2022-11-04 | 凯麦拉医疗公司 | Smarca降解剂和其用途 |
| CN113149981B (zh) * | 2020-01-22 | 2022-07-05 | 苏州德亘生物医药有限公司 | 一种降解雄激素受体的蛋白降解靶向嵌合体 |
| MX2022010952A (es) | 2020-03-05 | 2022-10-07 | C4 Therapeutics Inc | Compuestos para la degradacion dirigida de brd9. |
| CN113387930B (zh) * | 2020-03-11 | 2022-07-12 | 苏州开拓药业股份有限公司 | 一种双官能化合物及其制备方法和用途 |
| US12528785B2 (en) | 2020-03-19 | 2026-01-20 | Kymera Therapeutics, Inc. | MDM2 degraders and uses thereof |
| EP4146642A1 (en) | 2020-05-09 | 2023-03-15 | Arvinas Operations, Inc. | Methods of manufacturing a bifunctional compound, ultrapure forms of the bifunctional compound, and dosage forms comprising the same |
| WO2021231927A1 (en) * | 2020-05-14 | 2021-11-18 | The Regents Of The University Of Michigan | Androgen receptor protein degraders with a tricyclic cereblon ligand |
| EP4153587A4 (en) * | 2020-05-18 | 2024-06-12 | Montelino Therapeutics, Inc. | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF THE ANDROGEN RECEPTOR |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| CR20230007A (es) * | 2020-06-12 | 2023-06-01 | Shanghai Jemincare Pharmaceuticals Co Ltd | Compuesto de ftalazinona, y método de preparación y uso médico de este. |
| TW202216690A (zh) * | 2020-06-24 | 2022-05-01 | 美商西建公司 | Ｃｅｒｅｂｌｏｎ結合化合物、其組合物及使用該等物質之治療方法 |
| ES3048462T3 (en) * | 2020-06-24 | 2025-12-10 | Celgene Corp | Cereblon binding compounds, compositions thereof, and methods of treatment therewith |
| AR122723A1 (es) * | 2020-06-24 | 2022-09-28 | Celgene Corp | Compuestos de unión de cereblon, composiciones de los mismos, y métodos de tratamiento con los mismos |
| WO2022032026A1 (en) | 2020-08-05 | 2022-02-10 | C4 Therapeutics, Inc. | Compounds for targeted degradation of ret |
| WO2022047145A1 (en) | 2020-08-28 | 2022-03-03 | Arvinas Operations, Inc. | Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use |
| CN114163444B (zh) * | 2020-09-11 | 2023-07-14 | 江苏恒瑞医药股份有限公司 | 一种用于雄激素受体蛋白靶向降解的嵌合体化合物、其制备方法及其在医药上的应用 |
| US12162859B2 (en) | 2020-09-14 | 2024-12-10 | Arvinas Operations, Inc. | Crystalline and amorphous forms of a compound for the targeted degradation of estrogen receptor |
| CN114181277A (zh) * | 2020-09-15 | 2022-03-15 | 江苏恒瑞医药股份有限公司 | 一种用于雄激素受体蛋白靶向降解的嵌合体化合物、其制备方法及其在医药上的应用 |
| CN113527273B (zh) * | 2020-10-28 | 2023-08-22 | 中国药科大学 | 靶向泛素化降解hmgcr的化合物或其可药用的盐、制备方法及用途 |
| CN114262319B (zh) * | 2020-12-01 | 2023-05-05 | 南昌奥瑞药业有限公司 | 一类双功能分子、其制备方法及其应用 |
| WO2022120355A1 (en) | 2020-12-02 | 2022-06-09 | Ikena Oncology, Inc. | Tead degraders and uses thereof |
| TW202241891A (zh) | 2020-12-30 | 2022-11-01 | 美商凱麥拉醫療公司 | Irak降解劑及其用途 |
| TWI813106B (zh) * | 2020-12-30 | 2023-08-21 | 財團法人工業技術研究院 | 雄性激素受體結合分子及其用途 |
| EP4277901A1 (en) | 2021-01-13 | 2023-11-22 | Monte Rosa Therapeutics, Inc. | Isoindolinone compounds |
| US12171768B2 (en) | 2021-02-15 | 2024-12-24 | Kymera Therapeutics, Inc. | IRAK4 degraders and uses thereof |
| MX2023011241A (es) | 2021-03-23 | 2023-10-03 | Nuvation Bio Inc | Compuestos dirigidos a receptores de hormonas nucleares contra el cancer. |
| CR20230516A (es) | 2021-04-16 | 2024-01-23 | Arvinas Operations Inc | Moduladores de la proteólisis bcl6 y métodos de uso asociados |
| WO2022235585A1 (en) | 2021-05-03 | 2022-11-10 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| KR20240017814A (ko) | 2021-05-05 | 2024-02-08 | 바이오젠 엠에이 인코포레이티드 | 브루톤 티로신 키나제의 분해를 표적으로 하는 화합물 |
| IL308314A (en) | 2021-05-07 | 2024-01-01 | Kymera Therapeutics Inc | CDK2 compounds and their uses |
| CN117580575A (zh) * | 2021-06-17 | 2024-02-20 | 南京明德新药研发有限公司 | 戊二酰亚胺取代的异噁唑稠环化合物及其应用 |
| JP2024526191A (ja) * | 2021-06-25 | 2024-07-17 | セルジーン コーポレーション | セレブロン結合化合物、その組成物及びそれによる治療方法 |
| EP4359406A4 (en) * | 2021-06-25 | 2025-05-21 | Celgene Corporation | CEREBLON-BINDING COMPOUNDS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT USING THEM |
| EP4366834A1 (en) | 2021-07-07 | 2024-05-15 | Biogen MA Inc. | Compounds for targeting degradation of irak4 proteins |
| US20240343733A1 (en) | 2021-07-07 | 2024-10-17 | Biogen Ma Inc. | Compounds for targeting degradation of irak4 proteins |
| CN115772210A (zh) * | 2021-09-08 | 2023-03-10 | 苏州开拓药业股份有限公司 | 硫代乙内酰脲化合物或其药用盐的无定形物、晶体、药物组合物、制备方法和用途 |
| US11981672B2 (en) | 2021-09-13 | 2024-05-14 | Montelino Therapeutics Inc. | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor |
| US20240408106A1 (en) * | 2021-09-13 | 2024-12-12 | Montelino Therapeutics, Inc. | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor |
| JPWO2023054549A1 (enExample) | 2021-09-30 | 2023-04-06 | ||
| WO2023076161A1 (en) | 2021-10-25 | 2023-05-04 | Kymera Therapeutics, Inc. | Tyk2 degraders and uses thereof |
| AR127505A1 (es) | 2021-10-29 | 2024-01-31 | Kymera Therapeutics Inc | Degradadores irak-4 y síntesis de los mismos |
| EP4438603A4 (en) | 2021-11-25 | 2025-06-11 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | CHIMERIC COMPOUND FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR PROTEIN, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF |
| WO2023147594A2 (en) | 2022-01-31 | 2023-08-03 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| IL316803A (en) | 2022-06-06 | 2025-01-01 | C4 Therapeutics Inc | Bicyclic glutarimide-modified cervalon-binding agents |
| JP2025521686A (ja) | 2022-06-27 | 2025-07-10 | リレー セラピューティクス， インコーポレイテッド | エストロゲン受容体アルファ分解剤及びその使用 |
| WO2024006776A1 (en) | 2022-06-27 | 2024-01-04 | Relay Therapeutics, Inc. | Estrogen receptor alpha degraders and medical use thereof |
| WO2024037616A1 (zh) * | 2022-08-19 | 2024-02-22 | 正大天晴药业集团股份有限公司 | 包含环己基的化合物 |
| WO2024050016A1 (en) | 2022-08-31 | 2024-03-07 | Oerth Bio Llc | Compositions and methods for targeted inhibition and degradation of proteins in an insect cell |
| WO2024054591A1 (en) | 2022-09-07 | 2024-03-14 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use |
| WO2024064358A1 (en) | 2022-09-23 | 2024-03-28 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| WO2024073507A1 (en) | 2022-09-28 | 2024-04-04 | Theseus Pharmaceuticals, Inc. | Macrocyclic compounds and uses thereof |
| AU2024212035A1 (en) | 2023-01-26 | 2025-08-14 | Arvinas Operations, Inc. | Cereblon-based kras degrading protacs ans uses related thereto |
| WO2024165050A1 (en) * | 2023-02-10 | 2024-08-15 | Aubrak Therapeutics | Proteolysis-targeting chimera (protac) compounds and uses thereof field |
| WO2024211154A2 (en) * | 2023-04-03 | 2024-10-10 | Wisconsin Alumni Research Foundation | Ferritin-targeting protacs and methods of inducing pyroptosis |
| WO2025049555A1 (en) | 2023-08-31 | 2025-03-06 | Oerth Bio Llc | Compositions and methods for targeted inhibition and degradation of proteins in an insect cell |
| WO2025068704A1 (en) | 2023-09-28 | 2025-04-03 | Phoremost Limited | Methods of protein engineering and functional screening |
| WO2025122895A1 (en) | 2023-12-08 | 2025-06-12 | Arvinas Operations, Inc. | Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy |
Family Cites Families (112)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1285916B1 (en) | 1996-07-24 | 2010-03-10 | Celgene Corporation | Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and -1-oxoisoindolines and method of reducing TNF alpha levels |
| CA2287387C (en) | 1997-05-14 | 2010-02-16 | Sloan-Kettering Institute For Cancer Research | Methods and compositions for destruction of selected proteins |
| US6306663B1 (en) | 1999-02-12 | 2001-10-23 | Proteinex, Inc. | Controlling protein levels in eucaryotic organisms |
| CA2372176A1 (en) | 1999-05-05 | 2000-11-09 | Merck & Co., Inc. | Novel prolines as antimicrobial agents |
| BR0111298A (pt) | 2000-06-28 | 2005-05-10 | Bristol Myers Squibb Co | Moduladores seletivos dos receptores de andrógenos e métodos para identificação, projeto e uso dos mesmos |
| US7041298B2 (en) | 2000-09-08 | 2006-05-09 | California Institute Of Technology | Proteolysis targeting chimeric pharmaceutical |
| US7208157B2 (en) | 2000-09-08 | 2007-04-24 | California Institute Of Technology | Proteolysis targeting chimeric pharmaceutical |
| US20030045552A1 (en) | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| WO2002066512A1 (en) | 2001-02-16 | 2002-08-29 | E.I. Dupont De Nemours And Company | Angiogenesis-inhibitory tripeptides, compositions and their methods of use |
| HN2002000136A (es) | 2001-06-11 | 2003-07-31 | Basf Ag | Inhibidores de la proteasa del virus hiv, compuestos que contienen a los mismos, sus usos farmaceuticos y los materiales para su sintesis |
| TWI263640B (en) | 2001-12-19 | 2006-10-11 | Bristol Myers Squibb Co | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| WO2004005248A1 (en) | 2002-07-02 | 2004-01-15 | Novartis Ag | Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap) |
| EP1651595A2 (en) | 2003-05-30 | 2006-05-03 | Rigel Pharmaceuticals, Inc. | Ubiquitin ligase inhibitors |
| CN1960728A (zh) | 2004-01-16 | 2007-05-09 | 密歇根大学董事会 | 构象受限的smac模拟物及其应用 |
| CA2558615C (en) | 2004-03-23 | 2013-10-29 | Genentech, Inc. | Azabicyclo-octane inhibitors of iap |
| PL2253614T3 (pl) | 2004-04-07 | 2013-03-29 | Novartis Ag | Inhibitory IAP |
| SI1778718T1 (sl) | 2004-07-02 | 2015-01-30 | Genentech, Inc. | Inhibitorji IAP |
| JP4874965B2 (ja) | 2004-07-08 | 2012-02-15 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | アンドロゲン調節剤 |
| AU2005280908A1 (en) | 2004-09-09 | 2006-03-16 | Chugai Seiyaku Kabushiki Kaisha | Novel imidazolidine derivative and use thereof |
| KR20120127754A (ko) | 2004-12-20 | 2012-11-23 | 제넨테크, 인크. | Ｉａｐ의 피롤리딘 억제제 |
| DK1851200T3 (da) | 2005-02-25 | 2014-04-14 | Tetralogic Pharm Corp | Dimere iap-inhibitorer |
| CN100383139C (zh) | 2005-04-07 | 2008-04-23 | 天津和美生物技术有限公司 | 可抑制细胞释放肿瘤坏死因子的哌啶-2，6-二酮衍生物 |
| WO2006113942A2 (en) | 2005-04-20 | 2006-10-26 | Schering Corporation | Method of inhibiting cathepsin activity |
| AU2006248109B2 (en) * | 2005-05-13 | 2012-11-15 | The Regents Of The University Of California | Diarylhydantoin compounds |
| AU2007245022A1 (en) | 2006-03-29 | 2007-11-08 | The Regents Of The University Of California | Diarylthiohydantoin compounds |
| WO2007027527A2 (en) | 2005-08-31 | 2007-03-08 | Celgene Corporation | Isoindole-imide compounds and compositions comprising and methods of using the same |
| WO2007106670A2 (en) | 2006-03-03 | 2007-09-20 | Novartis Ag | N-formyl hydroxylamine compounds |
| WO2007101347A1 (en) | 2006-03-07 | 2007-09-13 | Aegera Therapeutics Inc. | Bir domain binding compounds |
| CN101032483B (zh) * | 2006-03-09 | 2011-05-04 | 陈德桂 | 调节雄激素受体活性的乙内酰脲衍生物及其应用 |
| WO2007130626A2 (en) | 2006-05-05 | 2007-11-15 | The Regents Of The University Of Michigan | Bivalent smac mimetics and the uses thereof |
| WO2008011392A2 (en) | 2006-07-20 | 2008-01-24 | Ligand Pharmacueticals Incorporated | Proline urea ccr1 antagonists for the treatment of autoimmune diseases or inflammation |
| US20100056495A1 (en) | 2006-07-24 | 2010-03-04 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
| CL2007002513A1 (es) | 2006-08-30 | 2008-04-04 | Celgene Corp Soc Organizada Ba | Compuestos derivados de isoindolina sustituidos, compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento y prevencion de enfermedades tales como cancer, dolor, degeneracion macular, entre otras. |
| RU2448101C2 (ru) | 2006-08-30 | 2012-04-20 | Селджин Корпорейшн | 5-замещенные изоиндолиновые соединения |
| WO2008054827A2 (en) | 2006-11-03 | 2008-05-08 | Pharmacyclics, Inc. | Bruton's tyrosine kinase activity probe and method of using |
| WO2008109057A1 (en) | 2007-03-02 | 2008-09-12 | Dana-Farber Cancer Institute, Inc. | Organic compounds and their uses |
| CA2684169C (en) | 2007-04-12 | 2012-06-19 | Joyant Pharmaceuticals, Inc. | Smac mimetic dimers and trimers useful as anti-cancer agents |
| HRP20140885T1 (hr) | 2007-04-13 | 2014-11-21 | The Regents Of The University Of Michigan | Diazo bicikliäśki smac mimetici i njihove primjene |
| CA2683392A1 (en) | 2007-04-30 | 2008-11-06 | Genentech, Inc. | Inhibitors of iap |
| WO2008144925A1 (en) | 2007-05-30 | 2008-12-04 | Aegera Therapeutics Inc. | Iap bir domain binding compounds |
| JP5282091B2 (ja) | 2007-07-25 | 2013-09-04 | ブリストル−マイヤーズ スクイブ カンパニー | トリアジンキナーゼ阻害剤 |
| KR20100051808A (ko) * | 2007-07-31 | 2010-05-18 | 앤드로사이언스 코포레이션 | 안드로겐 수용체 분해 강화제를 포함한 조성물 및 탈모와 피부질환의 예방 또는 치료 방법 |
| EP2058312A1 (en) | 2007-11-09 | 2009-05-13 | Universita' degli Studi di Milano | SMAC mimetic compounds as apoptosis inducers |
| SI2358697T1 (sl) | 2008-10-29 | 2016-02-29 | Celgene Corporation | Spojine izoindolina za uporabo pri zdravljenju raka |
| US20120135089A1 (en) | 2009-03-17 | 2012-05-31 | Stockwell Brent R | E3 ligase inhibitors |
| WO2010141805A1 (en) | 2009-06-05 | 2010-12-09 | Janssen Pharmaceutica Nv | Heterocyclic amides as modulators of trpa1 |
| CA2768299C (en) | 2009-07-13 | 2018-03-20 | President And Fellows Of Harvard College | Bifunctional stapled polypeptides and uses thereof |
| AR078793A1 (es) | 2009-10-27 | 2011-12-07 | Orion Corp | Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros |
| EP2493879B1 (en) | 2009-10-28 | 2014-05-14 | Joyant Pharmaceuticals, Inc. | Dimeric smac mimetics |
| SG10202012179RA (en) | 2010-02-11 | 2021-01-28 | Celgene Corp | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| EP3124481B1 (en) | 2010-02-16 | 2018-03-28 | Aragon Pharmaceuticals, Inc. | Androgen receptor modulators and uses thereof |
| EP2588129A4 (en) | 2010-06-30 | 2014-07-09 | Univ Brandeis | ON SMALL MOLECULES TARGETED PROTEIN REMOVAL |
| AU2011305315A1 (en) | 2010-09-24 | 2013-03-28 | The Regents Of The University Of Michigan | Deubiquitinase inhibitors and methods for use of the same |
| CN103502275A (zh) | 2010-12-07 | 2014-01-08 | 耶鲁大学 | 融合蛋白的小分子疏水性标记和引起的其降解 |
| US20140243282A1 (en) | 2010-12-31 | 2014-08-28 | Satish Reddy Kallam | Methods and compositions for designing novel conjugate therapeutics |
| CA2831338C (en) * | 2011-04-21 | 2018-07-17 | Orion Corporation | Androgen receptor modulating carboxamides |
| EP2760845B1 (en) | 2011-09-27 | 2016-11-16 | Amgen Inc. | Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer |
| WO2013067151A1 (en) * | 2011-11-02 | 2013-05-10 | Medivation Prostate Therapeutics, Inc. | Treatment methods using diarylthiohydantoin derivatives |
| WO2013067142A1 (en) * | 2011-11-02 | 2013-05-10 | Medivation Technologies, Inc. | Compounds and treatment methods |
| WO2013071039A1 (en) | 2011-11-09 | 2013-05-16 | Ensemble Therapeutics | Macrocyclic compounds for inhibition of inhibitors of apoptosis |
| EP2776409B1 (en) | 2011-11-09 | 2016-02-03 | Ensemble Therapeutics Corporation | Macrocyclic compounds for inhibition of inhibitors of apoptosis |
| EP3608317A1 (en) | 2012-01-12 | 2020-02-12 | Yale University | Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase |
| WO2013106646A2 (en) | 2012-01-12 | 2013-07-18 | Yale University | Compounds and methods for the inhibition of vcb e3 ubiquitin ligase |
| US20150119435A1 (en) | 2012-05-11 | 2015-04-30 | Yale University | Compounds useful for promoting protein degradation and methods using same |
| US9365576B2 (en) | 2012-05-24 | 2016-06-14 | Novartis Ag | Pyrrolopyrrolidinone compounds |
| SG11201406889WA (en) | 2012-05-30 | 2015-02-27 | Hoffmann La Roche | Substituted pyrrolidine-2-carboxamides |
| WO2014011712A1 (en) | 2012-07-10 | 2014-01-16 | Bristol-Myers Squibb Company | Iap antagonists |
| DK2880447T3 (da) | 2012-07-31 | 2019-08-12 | Novartis Ag | Markører forbundet med følsomhed for hæmmere af human double minute 2 (MDM2) |
| US9453048B2 (en) | 2012-08-09 | 2016-09-27 | Bristol-Myers Squibb Company | IAP antagonists |
| HRP20202050T1 (hr) | 2012-09-04 | 2021-02-19 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Derivati imidazolina, postupci njihove pripreme i njihova medicinska primjena |
| TWI586668B (zh) | 2012-09-06 | 2017-06-11 | 第一三共股份有限公司 | 二螺吡咯啶衍生物之結晶 |
| EP2897949B1 (en) | 2012-09-18 | 2018-01-10 | Bristol-Myers Squibb Company | Iap antagonists |
| US9603889B2 (en) | 2012-10-02 | 2017-03-28 | Bristol-Myers Squibb Company | IAP antagonists |
| AR093404A1 (es) | 2012-11-09 | 2015-06-03 | Bristol Myers Squibb Co | Compuestos macrociclicos que modulan la actividad de los inhibidores de la apoptosis |
| WO2014100071A2 (en) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | Substituted pyrrolopyrimidines as hdm2 inhibitors |
| TW201429969A (zh) | 2012-12-20 | 2014-08-01 | Merck Sharp & Dohme | 作爲ｈｄｍ２抑制劑之經取代咪唑吡啶 |
| EP2752191A1 (en) | 2013-01-07 | 2014-07-09 | Sanofi | Compositions and methods using hdm2 antagonist and mek inhibitor |
| GB201311910D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel Compounds |
| NL2011274C2 (en) | 2013-08-06 | 2015-02-09 | Illumicare Ip B V 51 | Groundbreaking platform technology for specific binding to necrotic cells. |
| EP2961735B1 (en) | 2013-02-28 | 2017-09-27 | Amgen Inc. | A benzoic acid derivative mdm2 inhibitor for the treatment of cancer |
| AU2014236812B2 (en) | 2013-03-14 | 2018-03-01 | Amgen Inc. | Heteroaryl acid morpholinone compounds as MDM2 inhibitors for the treatment of cancer |
| TW201534586A (zh) | 2013-06-11 | 2015-09-16 | Orion Corp | 新穎ｃｙｐ１７抑制劑／抗雄激素劑 |
| GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| WO2015006524A1 (en) | 2013-07-12 | 2015-01-15 | Bristol-Myers Squibb Company | Iap antagonists |
| US20160058872A1 (en) | 2014-04-14 | 2016-03-03 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| WO2015160845A2 (en) * | 2014-04-14 | 2015-10-22 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| TW201613916A (en) | 2014-06-03 | 2016-04-16 | Gilead Sciences Inc | TANK-binding kinase inhibitor compounds |
| US20160022642A1 (en) | 2014-07-25 | 2016-01-28 | Yale University | Compounds Useful for Promoting Protein Degradation and Methods Using Same |
| US10071164B2 (en) | 2014-08-11 | 2018-09-11 | Yale University | Estrogen-related receptor alpha based protac compounds and associated methods of use |
| US9694084B2 (en) | 2014-12-23 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| JP6815318B2 (ja) | 2014-12-23 | 2021-01-20 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | 二官能性分子によって標的化タンパク質分解を誘導する方法 |
| HK1245791A1 (zh) | 2015-01-20 | 2018-08-31 | 阿尔维纳斯运营股份有限公司 | 用於雄激素受体的靶向降解的化合物和方法 |
| US12312316B2 (en) | 2015-01-20 | 2025-05-27 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| GB201504314D0 (en) | 2015-03-13 | 2015-04-29 | Univ Dundee | Small molecules |
| HK1249058A1 (zh) | 2015-03-18 | 2018-10-26 | Arvinas, Inc. | 用於增强靶向蛋白质降解的化合物和方法 |
| GB201506872D0 (en) | 2015-04-22 | 2015-06-03 | Ge Oil & Gas Uk Ltd | Novel compounds |
| WO2016197114A1 (en) | 2015-06-05 | 2016-12-08 | Arvinas, Inc. | Tank-binding kinase-1 protacs and associated methods of use |
| WO2017007612A1 (en) | 2015-07-07 | 2017-01-12 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| CA2988430A1 (en) | 2015-07-10 | 2017-01-19 | Arvinas, Inc. | Mdm2-based modulators of proteolysis and associated methods of use |
| KR20180029061A (ko) | 2015-07-13 | 2018-03-19 | 아비나스 인코포레이티드 | 단백질 분해의 알라닌계 조절인자 및 관련된 이용 방법 |
| EP3331905B1 (en) | 2015-08-06 | 2022-10-05 | Dana-Farber Cancer Institute, Inc. | Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses |
| WO2017024317A2 (en) | 2015-08-06 | 2017-02-09 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| WO2017030814A1 (en) | 2015-08-19 | 2017-02-23 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| EP3370715A4 (en) | 2015-11-02 | 2019-05-15 | Yale University | CHIMERIC COMPOUNDS PROVIDED AGAINST PROTEOLYSIS AND METHOD FOR THE PRODUCTION AND USE THEREOF |
| US20170281784A1 (en) | 2016-04-05 | 2017-10-05 | Arvinas, Inc. | Protein-protein interaction inducing technology |
| US10584101B2 (en) | 2016-10-11 | 2020-03-10 | Arvinas, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| WO2018102067A2 (en) | 2016-11-01 | 2018-06-07 | Arvinas, Inc. | Tau-protein targeting protacs and associated methods of use |
| JP6957620B2 (ja) | 2016-12-01 | 2021-11-02 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | エストロゲン受容体分解物質としてのテトラヒドロナフタレン誘導体およびテトラヒドロイソキノリン誘導体 |
| KR20250117470A (ko) | 2016-12-23 | 2025-08-04 | 아비나스 오퍼레이션스, 인코포레이티드 | 급속 진행성 섬유육종 폴리펩티드의 표적화 분해를 위한 화합물 및 방법 |
| US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
-
2016
- 2016-01-20 HK HK18105390.5A patent/HK1245791A1/zh unknown
- 2016-01-20 JP JP2017556797A patent/JP6817962B2/ja active Active
- 2016-01-20 CA CA2974367A patent/CA2974367A1/en active Pending
- 2016-01-20 HK HK18106942.6A patent/HK1247204A1/zh unknown
- 2016-01-20 KR KR1020227006656A patent/KR20220029783A/ko not_active Ceased
- 2016-01-20 EP EP16740708.9A patent/EP3247708A4/en active Pending
- 2016-01-20 KR KR1020177023120A patent/KR102110566B1/ko active Active
- 2016-01-20 US US15/002,303 patent/US11352351B2/en active Active
- 2016-01-20 MX MX2017009454A patent/MX390189B/es unknown
- 2016-01-20 KR KR1020207013156A patent/KR20200052995A/ko not_active Abandoned
- 2016-01-20 KR KR1020227037454A patent/KR102564925B1/ko active Active
- 2016-01-20 BR BR112017015497-8A patent/BR112017015497A2/pt not_active Application Discontinuation
- 2016-01-20 KR KR1020237026413A patent/KR20230119040A/ko not_active Ceased
- 2016-01-20 AU AU2016209349A patent/AU2016209349B2/en active Active
- 2016-01-20 CN CN201680014250.8A patent/CN107428734A/zh active Pending
- 2016-01-20 WO PCT/US2016/014187 patent/WO2016118666A1/en not_active Ceased
-
2017
- 2017-07-19 MX MX2022002016A patent/MX2022002016A/es unknown
-
2018
- 2018-07-27 US US16/048,191 patent/US20180346461A1/en not_active Abandoned
-
2020
- 2020-03-17 JP JP2020046636A patent/JP2020111590A/ja active Pending
- 2020-08-07 AU AU2020213376A patent/AU2020213376B2/en active Active
-
2021
- 2021-10-27 AU AU2021257970A patent/AU2021257970A1/en not_active Abandoned
-
2022
- 2022-12-20 US US18/085,500 patent/US20240059686A1/en active Pending
- 2022-12-23 JP JP2022206686A patent/JP2023040072A/ja active Pending
-
2023
- 2023-12-19 AU AU2023285742A patent/AU2023285742A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018502925A5 (enExample) | ||
| RU2020108515A (ru) | Соединения и способы целевого расщепления андрогенного рецептора | |
| JP2009532486A5 (enExample) | ||
| NZ588830A (en) | Inhibitors of protein kinases | |
| JP2017526677A5 (enExample) | ||
| JP2011509309A5 (enExample) | ||
| JP2011219498A5 (enExample) | ||
| JP2012522053A5 (enExample) | ||
| JP2018522879A5 (enExample) | ||
| JP2016506962A5 (enExample) | ||
| RU2015118647A (ru) | Аминопиримидиновые соединения в качестве ингибиторов содержащих т790м мутантных egfr | |
| JP2018502906A5 (enExample) | ||
| JP2016506960A5 (enExample) | ||
| JP2012515225A5 (enExample) | ||
| JP2015500887A5 (enExample) | ||
| JP2015514808A5 (enExample) | ||
| TR201802944T4 (tr) | İlaç olarak azai̇ndazol veya di̇azai̇ndazol türünün türevleri̇ | |
| BRPI0815142B8 (pt) | forma cristalina do sal de dicloridrato ((1s)-1-(((2s)-2-(5-(4'-(2-((2s)-1-((2s)-2-((metoxicarbonil)amino)-3-metilbutanoil)-2-pirrolidinil)-1h-imidazol-5-il)-4-bifenilil)-1h-imidazol-2-il)-1-pirrolidinil)carbonil)-2-metilpropil)carbamato de metila. | |
| JP2014511892A5 (enExample) | ||
| RU2007134380A (ru) | Антибактериальные производные пиперидина | |
| JP2011515483A5 (enExample) | ||
| JP2010524957A5 (enExample) | ||
| JP2016506961A5 (enExample) | ||
| JP2016503009A5 (enExample) | ||
| JP2014532730A5 (ja) | オピオイド受容体の調節物質およびそれを含む薬学的組成物 |